Loading...
•
Jun 30, 2024
Inozyme Q2 2024 Earnings Report
Inozyme Pharma reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
Key Takeaways
Inozyme Pharma reported a net loss of $27.0 million for Q2 2024. The company's cash, cash equivalents, and short-term investments were $144.5 million as of June 30, 2024, which are expected to fund operations into Q4 2025. The company is advancing INZ-701 through clinical programs with several milestones expected by year-end.
Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024
Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024
Interim data from SEAPORT 1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024
Cash, cash equivalents, and short-term investments as of June 30, 2024, expected to fund operations into the fourth quarter of 2025
Forward Guidance
Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of June 30, 2024, will enable the Company to fund cash flow requirements into Q4 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...